Citation Impact
Citing Papers
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
2010 Standout
Nasopharyngeal carcinoma
2005 Standout
Establishing the Diagnosis of Lung Cancer
2013 Standout
Prevalence and Patterns of Bone Metastases Detected with Positron Emission Tomography Using F-18 FDG
2003
Staging by Positron Emission Tomography Predicts Survival in Patients With Non-small Cell Lung Cancer
2001
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Imaging of Pleural Disease
2006
Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center
2002
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Head and neck cancer
2008 Standout
High Performance of <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography and Contrast-Enhanced CT in a Rapid Outpatient Diagnostic Program for Patients with Suspected Lung Cancer
2013 Standout
Causes and Consequences of Increased Glucose Metabolism of Cancers
2008
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
From Krebs to clinic: glutamine metabolism to cancer therapy
2016 Standout
Preoperative Staging of Non–Small-Cell Lung Cancer with Positron-Emission Tomography
2000
F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma
2001
Management of pleural infection in adults: British Thoracic Society pleural disease guideline 2010
2010 Standout
Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010
2010 Standout
Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non–small cell lung cancer
2003
Regulation of cancer cell metabolism
2011 Standout
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review
2001
Glycotherapy: New Advances Inspire a Reemergence of Glycans in Medicine
2013 StandoutNobel
The Emerging Hallmarks of Cancer Metabolism
2016 Standout
CT and 18F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers
2001
Methods for Staging Non-small Cell Lung Cancer
2013
Evaluation of Pleural Disease With 18-Fluorodeoxyglucose Positron Emission Tomography Imaging
2004
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
2009 Standout
Staging of non-small cell lung cancer: consensus, controversies and challenges
2001
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration
2008
High rate of detection of unsuspected distant metastases by PET in apparent Stage III non–small-cell lung cancer: implications for radical radiation therapy
2001
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results
2000
Metaanalyse zum Stellenwert der Positronen-Emissions-Tomographie mit F-18-Fluorodesoxyglukose (FDG-PET) bei Lungentumoren1 - Diskussionsbasis der deutschen Konsensus-Konferenz Onko-PET 2000 -
2001
Meta-analysis
2011
Revised Response Criteria for Malignant Lymphoma
2007 Standout
Positron-Emission Tomography and Assessment of Cancer Therapy
2006
Positron Emission Tomography Is Superior to Computed Tomography Scanning for Response-Assessment After Radical Radiotherapy or Chemoradiotherapy in Patients With Non–Small-Cell Lung Cancer
2003
PET-based treatment planning in radiotherapy: a new standard?
2007
18F-FDG PET/CT Imaging In Oncology
2011
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
2005
Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer.
2001
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Works of Frédéric Daenen being referenced
Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer
1998
Typical Appearance of Mesothelioma on an F-18 FDG Positron Emission Tomograph
2000
Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer
1999
[18FDG-PET applications in thoracic oncology].
2001